[Ip-health] Competition Commission of India - Policy Note on ‘Making Markets Work for Affordable Healthcare’

leena menghaney leenamenghaney at gmail.com
Wed Oct 24 18:57:19 PDT 2018

 Its seems that India's Competition Commission has released a policy note
to different ministries highlighting the high drug prices. Very interesting
development. Impact on making cancer drug prices more affordable -
especially the now available biosimilars - could be significant - if trade
margins charged by hospitals could be controlled. Many women with breast
cancer have been forced to buy trastuzumab from hospital pharmacies at
double the price available from the distributors for the 440 and 150 dose
vial. However the CCI has not addressed the issue of high cancer prices for
patented medicines such as lapatinib, sunitinib etc due to lack of

See link to the CCI press release here, which almost reads like a policy
document:  file:///C:/Users/msfuser/AppData/Local/Temp/PressRelease.pdf

Hindu Business Line: Regulation mooted to stop hospitals from forcing
patients to buy drugs from in-house pharmacies

Times of India - CCI points at "unreasonably high margins" for high drug
In a policy note, the anti-trust  regulator said high margins are a form of
incentive and an indirect  marketing tool employed by drug companies.
Essential medicines  constitute over 60% of out-of-pocket expenditure on
healthcare in India.  Link:

Biospectrum: CCI brings out policy note on Affordable Healthcare

Outlook: High trade margins pushing drug prices higher, says CCI policy note

ET: High drug prices due to unreasonable margins of companies: CCI

Business Standard: High trade margins pushing drug prices higher, says CCI
policy note

Leena Menghaney
Mobile: 9811365412

More information about the Ip-health mailing list